- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advocate for Policies and Actions
- Build Rapid-Response Networks
- Improve Research Conduct
- Provide Tools for Decision-Making
- Translate & Share the Latest Information
- Our FocusInterventions to End the Epidemic
- AIDS Vaccines
- Combination Prevention
- Male and Female Condoms
- Hormonal Contraceptives and HIV
- Multipurpose Prevention Technologies
- Treatment as Prevention
- Voluntary Medical Male Circumcision
- How Research Happens
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.
Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit – if they can access this potentially life-saving option.
So far, PrEP’s implementation has been piecemeal and incomplete. The pace and demand are picking up in the United States. In other countries, including some where the research took place, there is limited or no access. For maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research, and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills, or quarterly injections—could help improve adherence and achieve PrEP’s full potential.
What We're Reading